A Review On The Role of Angiotensin Receptor-Neprilysin Inhibitors in Heart Failure with Reduced Ejection Fraction

Heart failure with reduced ejection fraction (HFrEF) is a clinical syndrome characterized by the heart’s inability to pump sufficient blood, leading to symptoms such as dyspnea, fatigue, and fluid retention. Traditional treatment approaches have included angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), beta-blockers, and mineralocorticoid receptor antagonists (MRAs). However, despite optimal medical therapy, many patients continue to experience significant morbidity and mortality. The advent of Angiotensin Receptor-Neprilysin Inhibitors (ARNis) represents a significant advancement in the treatment of HFrEF. ARNis, such as the combination of sacubitril and valsartan, provide a dual mechanism of action by simultaneously inhibiting the renin-angiotensin-aldosterone system (RAAS) through angiotensin II receptor blockade and enhancing natriuretic peptide activity by inhibiting neprilysin, an enzyme responsible for the degradation of natriuretic peptides. This combination has shown to provide superior clinical outcomes compared to traditional therapies. The pivotal PARADIGM-HF trial demonstrated that sacubitril/valsartan significantly reduced the risk of cardiovascular death and heart failure hospitalization compared to enalapril, an ACEI, in patients with HFrEF. The benefits of ARNis extend beyond the improvement of hemodynamics; they also include beneficial effects on myocardial remodeling, reduction in hospitalizations, and improved quality of life. However, ARNis are not without challenges. The most common adverse effects include hypotension, hyperkalemia, and renal dysfunction, which require careful patient selection and monitoring. Additionally, the cost of ARNis may pose a barrier to widespread use, although their long-term benefits may offset initial expenditures.